Last reviewed · How we verify
NCT05401422
Brimonidine in Rosacea
NA trial testing treatment in Rosacea in 45 participants. Status unknown.
15 September 2022
Quick facts
| Lead sponsor | Cairo University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 25 May 2022 |
| Primary completion | 15 September 2022 |
| Estimated completion | 15 September 2022 |
Drugs / interventions tested
- treatment — full drug profile →
Conditions studied
- Rosacea — all drugs for Rosacea →
Sponsor
Cairo University
Who can join
Adults 18 to 60, any sex, with Rosacea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rosacea is a chronic and relapsing inflammatory cutaneous disorder with highly variable prevalence worldwide.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05401422
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of treatment
Trials testing the same drug.
- NCT06885398 — Intra Arrest Ventilation in Human Cadavers II · NA · not yet recruiting
- NCT03153215 — Sildenafil in Sever Intrauterine Growth Retardation · NA · completed
- NCT02392455 — VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC) · completed
- NCT06172049 — Incidence of Colorectal Cancer in Southwest China: Based on SCC Database · completed
- NCT01154140 — A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplati · Phase 3 · completed
Other recruiting trials for Rosacea
Currently open trials in the same condition.
- NCT07296497 — Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety · NA · recruiting
- NCT06312813 — Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With · Phase 2 · recruiting
- NCT06072066 — Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammatio · NA · recruiting
- NCT05942248 — The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis · NA · recruiting
- NCT05928169 — Determinants of Chronic Inflammatory Skin Disease Trajectories · recruiting
Other Cairo University trials
Trials by the same sponsor.
- NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
- NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
- NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
- NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
- NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05401422 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cairo University
- Last refreshed: 2 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05401422.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing